A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults

StatusCompleted
PhasePhase 1
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Eligibility criteria expanded, about 5 words
  2. Primary and study completion dates: Aug 22, 2026 to Aug 21, 2026
    • Secondary endpoints: details revised at 3 of 3 entries
    v11
  3. Enrollment target: 53 to 32
    • Trial status: Recruiting to Active, Not Recruiting
    • Primary and study completion dates: Jun 4, 2026 to Aug 22, 2026
    • Site details revised
    v10
  4. 4 versions Re-verified since Aug 13, 2025, no change to tracked fieldsv6-v9
  5. Primary and study completion dates: Mar 27, 2026 to Jun 4, 2026v5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Mar 28, 2026 to Mar 27, 2026
    • Start date changed from estimate of Jun 23, 2025 to Jun 20, 2025
    • Site details revised
    v4
  2. Study sites: 0 to 1v3
  3. Primary and study completion dates: Mar 3, 2026 to Mar 28, 2026
    • Start date: May 27, 2025 to Jun 23, 2025
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
441 trials monitored
See 30 trials at risk
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-07999415) in healthy adult participants. This study is seeking volunteers aged 18 to 65 years old who do not have any major health issues. Some participants in this study will receive a single dose of PF-07999415 as a shot in the thigh, abdomen, or arm at the study clinic. Afterward, participants will stay in a hospital-like setting for 2 weeks, where they will be monitored for reactions to the study medicine. The study team will compare the experiences of people receiving PF-07999415 to those of the people who do not. This will help the study team decide if PF-07999415 is safe. Participants will take part in this study for 3 to 7 months. During this time, participants will stay at the healthcare facility for 2 weeks and then come back for study visits every 2-4 weeks until completing the study.
Trial Details
NCT Number NCT06965465
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Healthy
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov